Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8416 to 8430 of 8989 results

  1. Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

    Discontinued Reference number: GID-TA10151

    Technology appraisal guidance
    Discontinued

  2. Workplace health for employees with disabilities and long-term conditions

    Discontinued Reference number: GID-PHG58

    NICE guideline
    Discontinued

  3. Suspected cancer (QS124)

    April 2026: We have withdrawn this quality standard following the launch of the updated NICE guideline on suspected cancer: recognition and referral. An updated NICE quality standard for suspected cancer is being developed.  For any queries, please contact qualitystandards@nice.org.uk.

    Withdrawn quality standard

  4. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    Discontinued Reference number: GID-TA10583

    Technology appraisal guidance
    Discontinued

  5. Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]

    In development Reference number: GID-TA11655 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]

    In development Reference number: GID-TA11585 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

    In development Reference number: GID-TA11692 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease (IPG606)

    This guidance has been updated and replaced by NICE HealthTech guidance 733.

    Withdrawn guidance

  9. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

    Technology appraisal guidance
    Discontinued

  10. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    Discontinued Reference number: GID-TA11357

    Technology appraisal guidance
    Discontinued

  11. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    Discontinued Reference number: GID-TA11001

    Technology appraisal guidance
    Discontinued

  12. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    Discontinued Reference number: GID-TA11018

    Technology appraisal guidance
    Discontinued

  13. Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [ID6678]

    In development Reference number: GID-TA11805 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Discontinued Reference number: GID-TA11399

    Technology appraisal guidance
    Discontinued

  15. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued Reference number: GID-TAG387

    Technology appraisal guidance
    Discontinued